460 related articles for article (PubMed ID: 33678158)
21. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
22. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
23. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.
Yang H; Gou X; Feng C; Zhang Y; Chai F; Hong N; Ye Y; Wang Y; Gao B; Cheng J
J Transl Med; 2023 Jan; 21(1):4. PubMed ID: 36604653
[TBL] [Abstract][Full Text] [Related]
24. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
Front Immunol; 2022; 13():992060. PubMed ID: 36311733
[TBL] [Abstract][Full Text] [Related]
25. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():798474. PubMed ID: 35087523
[TBL] [Abstract][Full Text] [Related]
26. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
27. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
[TBL] [Abstract][Full Text] [Related]
29. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
30. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
31. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
33. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
34. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract][Full Text] [Related]
35. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
36. PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.
Deng S; Gu H; Chen Z; Liu Y; Zhang Q; Chen D; Yi S
Carcinogenesis; 2024 May; 45(5):351-357. PubMed ID: 38310539
[TBL] [Abstract][Full Text] [Related]
37. Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.
Wang Q; Liang J; Hu X; Gu S; Xu Q; Yan J
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34100918
[TBL] [Abstract][Full Text] [Related]
38. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
Wang Z; Wang X; Xu Y; Li J; Zhang X; Peng Z; Hu Y; Zhao X; Dong K; Zhang B; Gao C; Zhao X; Chen H; Cai J; Bai Y; Sun Y; Shen L
BMC Med; 2022 Apr; 20(1):133. PubMed ID: 35443723
[TBL] [Abstract][Full Text] [Related]
39. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
Zhao W; Liang Z; Yao Y; Ge Y; An G; Duan L; Yao J
Cancer Immunol Immunother; 2024 May; 73(7):131. PubMed ID: 38748299
[TBL] [Abstract][Full Text] [Related]
40. Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer.
Jiang Q; Chen H; Tang Z; Sun J; Ruan Y; Liu F; Sun Y
BMC Cancer; 2021 Sep; 21(1):1067. PubMed ID: 34587919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
